JP2000191526A - Composition for stimulating formation of bone and preventing and treating bone osteoporosis - Google Patents
Composition for stimulating formation of bone and preventing and treating bone osteoporosisInfo
- Publication number
- JP2000191526A JP2000191526A JP10370606A JP37060698A JP2000191526A JP 2000191526 A JP2000191526 A JP 2000191526A JP 10370606 A JP10370606 A JP 10370606A JP 37060698 A JP37060698 A JP 37060698A JP 2000191526 A JP2000191526 A JP 2000191526A
- Authority
- JP
- Japan
- Prior art keywords
- bone
- osteoporosis
- composition
- broth
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 210000000988 bone and bone Anatomy 0.000 title abstract description 41
- 208000001132 Osteoporosis Diseases 0.000 title abstract description 24
- 230000003405 preventing effect Effects 0.000 title abstract description 10
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 230000004936 stimulating effect Effects 0.000 title abstract 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims abstract description 36
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims abstract description 27
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 20
- 244000068988 Glycine max Species 0.000 claims abstract description 19
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims abstract description 15
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims abstract description 15
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000007240 daidzein Nutrition 0.000 claims abstract description 14
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000006539 genistein Nutrition 0.000 claims abstract description 12
- 229940045109 genistein Drugs 0.000 claims abstract description 12
- 229930182490 saponin Natural products 0.000 claims abstract description 12
- 150000007949 saponins Chemical class 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 11
- 230000003262 anti-osteoporosis Effects 0.000 claims description 9
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims description 8
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims description 8
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims description 8
- 235000010633 broth Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 20
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 208000010392 Bone Fractures Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 235000014347 soups Nutrition 0.000 abstract description 3
- 235000017709 saponins Nutrition 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- -1 daizin Natural products 0.000 abstract 1
- 239000000306 component Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000011164 ossification Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 230000008468 bone growth Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 4
- 235000008696 isoflavones Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013557 nattō Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000005428 food component Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 101100088138 Pinus taeda RPL10 gene Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007982 barbital buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- VJLOFJZWUDZJBX-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;chloride Chemical compound [Cl-].OCC[NH2+]CCO VJLOFJZWUDZJBX-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000000346 malonyl group Chemical group C(CC(=O)*)(=O)* 0.000 description 1
- 125000000695 menaquinone group Chemical group 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 235000013597 soy food Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Beans For Foods Or Fodder (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、骨有効成分として
サポニン,ダイジン,ダイゼイン,ゲニスチン及びゲニ
スティンを共に含む、骨粗鬆症などの代謝性骨疾患や骨
折などの予防及び治療に用いることができる骨成長及び
骨形成促進並びに抗骨粗鬆症組成物に関する。The present invention relates to a bone growth and metabolic bone disease such as osteoporosis and a bone fracture which contain both saponin, daidzin, daidzein, genistin and genistein as bone active ingredients. The present invention relates to an osteogenesis promoting and anti-osteoporotic composition.
【0002】[0002]
【従来の技術】老齢化に伴って骨量が減少し、骨粗鬆症
が引き起こりやすくなる。骨粗鬆症は、骨量の減少によ
り、骨折しやすくなる骨の病気であり、近年、国内外を
通じて多くの関心が持たれている。そのため、骨粗鬆症
は治療よりも予防することが重要な疾患と位置づけられ
ている。2. Description of the Related Art Bone mass decreases with aging, and osteoporosis tends to occur. Osteoporosis is a bone disease that is prone to fracture due to a decrease in bone mass. In recent years, osteoporosis has received much attention throughout Japan and overseas. Therefore, osteoporosis is positioned as a more important disease to prevent than to treat.
【0003】骨粗鬆症の治療薬としては、カルシウム,
活性型ビタミンD3,エストロゲン,カルシトニン,イ
プリフラボン,ビタミンK2及びビスホスホネート関連
化合物が用いられている。これらの薬物の作用は、骨組
織から骨塩を溶解するときに機能する破骨細胞の働きを
抑制することを主な作用としている。現在、開発中の骨
粗鬆症治療薬は、上記関連化合物の誘導体である。これ
ら薬物の使用は高価となり、骨粗鬆症と診断されて使用
が可能になるため、骨粗鬆症を予防することが不可能で
あり、骨粗鬆症を予防できる食品素材が求められてい
た。[0003] Therapeutic agents for osteoporosis include calcium,
Active vitamin D 3, estrogen, calcitonin, ipriflavone, vitamin K 2 and bisphosphonate related compounds have been used. The main effect of these drugs is to suppress the action of osteoclasts, which function when bone mineral is dissolved from bone tissue. Currently, osteoporosis therapeutics under development are derivatives of the above related compounds. Since the use of these drugs becomes expensive and can be used after being diagnosed with osteoporosis, it is impossible to prevent osteoporosis, and a food material capable of preventing osteoporosis has been demanded.
【0004】骨粗鬆症の予防のために、若年期から骨量
を増やすことが不可欠で、日常的に骨成長及び骨形成に
必要な栄養成分や、骨形成を促進する食品を積極的に摂
取することが極めて重要であることが認識されるように
なった。骨を強化する食品としては、現在、主にカルシ
ウムやビタミンDが利用されている。また、カルシウム
の腸管からの吸収を促進するカゼインホスホペプチドな
ども利用されている。更に、側鎖長の違いによりメナキ
ノン(MK)−1〜14として知られている食品中ビタ
ミンK2を利用することも考えられている。最近では、
ゲニスチンなどのイソフラボノイドが利用されようとし
ている。しかしながら、これらの物質を骨粗鬆症の予防
のために利用するには、多量を食品中に単独添加し強化
することが必要となり、食品の素材となり得ないため、
食品の機能性を高めても、そのし好性を低下させるなど
の問題がある。現在、骨粗鬆症を予防することを目的と
した適当な食品素材は開発されていない。In order to prevent osteoporosis, it is essential to increase bone mass from a young age, and to actively consume nutrients necessary for bone growth and bone formation and foods that promote bone formation on a daily basis. Has become recognized as very important. Currently, calcium and vitamin D are mainly used as foods for strengthening bones. Casein phosphopeptides that promote the absorption of calcium from the intestinal tract have also been used. Furthermore, it has been considered to utilize vitamin K 2 in foods known as menaquinones (MK) -1 to 14 depending on the difference in side chain length. recently,
Isoflavonoids such as genistin are being used. However, in order to utilize these substances for the prevention of osteoporosis, it is necessary to add a large amount to food alone and fortify it, and it cannot be used as a food material,
Even if the functionality of food is enhanced, there are problems such as a decrease in taste. At present, no suitable food material for preventing osteoporosis has been developed.
【0005】大豆種子は、イソフラボン成分を多く含ん
でいる。イソフラボンには、ダイジン,ゲニスチン,グ
リスチンとそれらにマロニル基が結合したものや、それ
らから糖がとれたダイゼインやゲニスティンが存在して
いる。近年、これらの成分の一部に、抗骨粗鬆症や女性
ホルモン活性などの生物学的作用が報告され注目を集め
ている。一方、イソフラボンが抗骨粗鬆症活性があるこ
とについての報告は散見されるが、主に、ダイゼインや
ゲニスティンを単品として用いたものである(Yama
guchi M, Gao YH: Res.Exp.
Med.,197:101−107,1997;Yam
aguchi M,Gao YH: Mol.Cel
l.Biochem.,178:377−382,19
98; Yamaguchi M,Gao YH:Bi
ochem.Pharmacol.,55:71−7
6,1998)。一方、大豆やその胚軸中には、サポニ
ン,ダイジン,ダイゼイン,ゲニスチン並びにゲニステ
ィンが高含有している。更に大豆からの納豆製造過程で
多量に生じる煮汁中には上記成分が高濃度に含有してお
り、この組成物は各々の単独成分よりも効果的な高い機
能性を有すると考えられるが、その知見は報告されてい
ない。また一方、大豆煮汁や大豆胚軸は食品として利用
されておらず、主に廃棄されている。これらに抗骨粗鬆
症作用などの機能性を見出すことができれば、機能性食
品として再利用することができる。[0005] Soybean seeds are rich in isoflavone components. The isoflavones include daidzin, genistin, glycine and those in which a malonyl group is bonded thereto, and daidzein or genistein from which sugar is removed. In recent years, biological effects such as anti-osteoporosis and female hormone activity have been reported on some of these components and have attracted attention. On the other hand, there are some reports that isoflavone has anti-osteoporosis activity, but it mainly uses daidzein or genistein as a single product (Yama).
guchi M, Gao YH: Res. Exp.
Med. , 197: 101-107, 1997;
Aguchi M, Gao YH: Mol. Cel
l. Biochem. 178: 377-382,19.
98; Yamaguchi M, Gao YH: Bi
ochem. Pharmacol. , 55: 71-7
6, 1998). On the other hand, soybeans and their hypocotyls contain high levels of saponin, daidzin, daidzein, genistin, and genistein. In addition, the above components are contained in a high concentration in the broth produced in a large amount during the process of producing natto from soybeans, and this composition is considered to have more effective and higher functionality than each single component. No findings were reported. On the other hand, soy broth and soybean hypocotyl are not used as food and are mainly discarded. If functionalities such as anti-osteoporosis effects can be found in these, they can be reused as functional foods.
【0006】[0006]
【発明が解決しようとする課題】骨粗鬆症の予防におい
ては、その予防のための食品の摂取は長期にわたるため
に安全性に優れることが絶対的に必要となる。従来用い
られているカルシウム、イソフラボンやビタミンK2な
どを食品に添加及び強化することについては、今日、そ
の安全性の面における知見が得られておらず、将来多く
の問題が生じる可能性が強い。しかしながら、大豆食品
中から生成する煮汁や胚軸は、天然食品素材であり、伝
統的食生活の経験から安全性が保障されている。そのた
め長期間にわたっての摂取は骨量の増加や骨粗鬆症の予
防のために極めて有効性が高い。この煮汁の骨量増加作
用や抗骨粗鬆症効果などの機能性については、これまで
に知られておらず、煮汁素材を用いた機能性食品の開発
もなされていない。本発明は、大豆煮汁の骨成長や骨形
成促進並びに抗骨粗鬆症の予防と治療を目的とした食品
組成物を得ることを目的としている。In the prevention of osteoporosis, the ingestion of foods for the prevention of osteoporosis for a long period of time requires absolutely excellent safety. Calcium conventionally used, such as isoflavones and vitamin K 2 for adding and enhanced foods, today, it is not obtained findings in terms of their safety, a strong possibility that many problems in the future arises . However, broth and hypocotyls produced from soy foods are natural food materials, and their safety is guaranteed from the experience of traditional eating habits. Therefore, long-term intake is extremely effective for increasing bone mass and preventing osteoporosis. Functionality such as a bone mass increasing effect and an anti-osteoporosis effect of this broth has not been known so far, and no functional food using a broth material has been developed. An object of the present invention is to obtain a food composition for promoting bone growth and bone formation of soybean broth and for preventing and treating anti-osteoporosis.
【0007】[0007]
【課題を解決するための手段】この発明の骨成長並びに
骨形成促進及び骨量減少防止効果を有する大豆煮汁の組
成物は、サポニン,ダイジン,ダイゼイン,ゲニスチ
ン,並びにゲニスティンを有効成分として含まれること
を特徴とする。Means for Solving the Problems The composition of soybean soup having the effects of promoting bone growth and bone formation and preventing bone loss according to the present invention contains saponin, daidzin, daidzein, genistin, and genistein as active ingredients. It is characterized by.
【0008】[0008]
【発明の実施の形態】本発明者は、骨代謝に影響を及ぼ
す食品成分に関して鋭意研究の結果、大豆煮汁組成物が
骨成分を増強させることを見出し、本発明を完成させた
ものである。本発明の組成物の作用及び効果は、4週齢
の幼若ラットに、本発明の煮汁液を経口投与し、ラット
の大腿骨の骨幹部及び骨幹端部組織の骨成分の変動を調
べることによって明らかにされた。すなわち、煮汁懸濁
液をラットに経口投与すると骨組織中の骨塩量としての
カルシウム量、骨石灰化促進酵素アルカリ性ホスファタ
ーゼ活性、並びに骨組織中の細胞数の指標としてのDN
A量を測定した結果、これらの全ての骨成分量が、有意
に上昇することを見出した。この結果から、本発明の煮
汁組成物は、骨成長並びに骨形成促進作用に基づく抗骨
粗鬆症作用を有し、骨塩量の減少を防止し得る作用を有
しており、骨粗鬆症や骨折の予防に有用であることが期
待された。BEST MODE FOR CARRYING OUT THE INVENTION The present inventors have conducted intensive studies on food components that affect bone metabolism, and have found that a soybean soup composition enhances bone components, thereby completing the present invention. The effect and effect of the composition of the present invention is to orally administer the boiled liquid of the present invention to 4-week-old young rats, and to examine changes in bone components of the femoral shaft and metaphyseal tissue of the rat. Revealed by That is, when a broth suspension is orally administered to rats, the amount of calcium as bone mineral in bone tissue, the activity of alkaline phosphatase, an enzyme promoting bone mineralization, and the number of cells as an indicator of the number of cells in bone tissue are increased.
As a result of measuring the amount of A, it was found that the amount of all these bone components significantly increased. From these results, the broth composition of the present invention has an anti-osteoporosis effect based on a bone growth and bone formation promoting effect, has an effect of preventing a decrease in the amount of bone mineral, and is useful for prevention of osteoporosis and fracture. Expected to be useful.
【0009】<実験例>以下の実験例によって、本発明
を更に詳細に説明する。 <実験方法の説明>幼若な雄性ウイスター系ラット6匹
を1群として用いた。納豆製造過程で生成する煮汁乾燥
粉末を精製蒸留水に懸濁し、100mg/mlの試験溶
液を調製した。煮汁乾燥粉末中には、サポニン(66m
g)、ダイジン(77mg)、ダイゼイン(0.6m
g)、ゲニスチン(58mg)及びゲニスティン(0.
6mg)を含有していた。この試験溶液をラットの体重
100g当り100mg/mlを胃ゾンデで経口投与し
た。投与は1日2回(午前10時と午後4時)14日間
行なった。最終投与の24時間後に、ラットはと殺し、
大腿骨を摘出した。対照群には、精製蒸留水を1ml/
100g体重を経口投与した。摘出した大腿骨は骨幹部
(皮質骨)と骨幹端部(海綿骨)に分け、骨成分の測定
に使用した。<Experimental Examples> The present invention will be described in more detail with reference to the following experimental examples. <Explanation of Experimental Method> Six young male Wistar rats were used as one group. The dried broth powder produced during the natto manufacturing process was suspended in purified distilled water to prepare a 100 mg / ml test solution. Saponin (66m
g), daidzin (77 mg), daidzein (0.6 m)
g), genistin (58 mg) and genistein (0.
6 mg). The test solution was orally administered at a dose of 100 mg / ml per 100 g of body weight of a rat using a gastric tube. The administration was performed twice a day (10 am and 4 pm) for 14 days. Twenty-four hours after the last dose, the rats are sacrificed,
The femur was removed. For the control group, purified distilled water was added at 1 ml /
100 g body weight was administered orally. The extracted femur was divided into a diaphyseal part (cortical bone) and a metaphyseal part (cancellous bone) and used for the measurement of bone components.
【0010】骨組織中カルシウム量の測定 大腿骨の骨幹部組織と骨幹端部組織を0.25Mショ糖
溶液中で軽く洗浄し、100℃で約6時間乾燥器中で乾
燥した。その乾燥重量を測定した後、試験管に入れ、濃
硝酸3mlを添加して、24時間120℃で分解した。
これを試料液として、カルシウム量を原子吸光光度計で
定量した。カルシウム量は、骨乾燥重量1g当りのmg
として表示した。Measurement of Calcium Content in Bone Tissue The diaphyseal tissue and metaphyseal tissue of the femur were lightly washed in a 0.25 M sucrose solution and dried in a dryer at 100 ° C. for about 6 hours. After measuring the dry weight, the mixture was placed in a test tube, 3 ml of concentrated nitric acid was added, and the mixture was decomposed at 120 ° C. for 24 hours.
Using this as a sample solution, the amount of calcium was quantified with an atomic absorption spectrophotometer. The amount of calcium is mg per 1 g of bone dry weight.
Displayed as
【0011】骨アルカリ性ホスファターゼ活性の測定 大腿骨の骨幹部組織と骨幹端部組織を冷0.25Mショ
糖溶液で洗浄後、冷6.5mMバルビタール緩衝液(p
H7.4)3m1中で破砕し、60秒間の超音波処理を
した。更に3000回転/分で5分間遠心処理し、その
上清画分を粗酵素溶液として用いた。骨アルカリ性ホス
ファターゼ活性は、Walter及びSchuttの方
法(Bergmeyer HU(ed).Method
s ofEnzymatic analysis,Vo
l.1−2,AcademicPress,New Y
ork, pp856−860,1965)に従って測
定した。酵素反応は、基質としてp−ニトロフェニルリ
ン酸ニナトリウムを含む0.1Mジエタノールアミン塩
酸緩衝液(pH9.8)2mlに酵素溶液0.05ml
を加えることにより反応を開始させた。反応は、37
℃、30分間インキュベーションすることにより行なっ
た。0.05N NaOH 10mlを加えることによ
り、反応を停止させ、遊離したp−ニトロフェノール量
(nmol)を分光光度計(405nm)で測定した。
酵素活性は、インキュベーションの1分間の反応で生成
したp−ニトロフェノール量(nmol)を、使用した
酵素蛋白質量(mg)当りで表示した。蛋白質の濃度は
Lowryらの方法(J.Biol.Chem.,19
3:265−273,1951)に準じて測定した。Measurement of Bone Alkaline Phosphatase Activity The diaphyseal tissue and metaphyseal tissue of the femur were washed with a cold 0.25 M sucrose solution and then cooled with a cold 6.5 mM barbital buffer (p
H7.4) Crushed in 3 ml and sonicated for 60 seconds. The mixture was further centrifuged at 3,000 rpm for 5 minutes, and the supernatant fraction was used as a crude enzyme solution. Bone alkaline phosphatase activity is determined by the method of Walter and Schutt (Bergmeyer HU (ed). Method).
s of Enzymatic analysis, Vo
l. 1-2, AcademicPress, New Y
ork, pp. 856-860, 1965). The enzymatic reaction is performed by adding 0.05 ml of the enzyme solution to 2 ml of 0.1 M diethanolamine hydrochloride buffer (pH 9.8) containing disodium p-nitrophenylphosphate as a substrate.
The reaction was started by adding. The reaction is 37
Incubation was performed at 30 ° C. for 30 minutes. The reaction was stopped by adding 10 ml of 0.05N NaOH, and the amount (nmol) of released p-nitrophenol was measured with a spectrophotometer (405 nm).
The enzyme activity was expressed in terms of the amount (nmol) of p-nitrophenol produced by the reaction for 1 minute of incubation per amount of enzyme protein used (mg). The protein concentration was determined by the method of Lowry et al. (J. Biol. Chem., 19).
3: 265-273, 1951).
【0012】骨組織中のデオキシリボ核酸(DNA)量
の測定 大腿骨の骨幹部組織と骨幹端部組織を冷0.25Mショ
糖液で洗浄し、水分除去後、湿重量を測定した。これを
0.1N NaOH 4.0ml中で破砕し、4℃、2
4時間振とう、抽出した。その後、3000回転/分で
5分間遠心処理し、その上清画分をDNA測定用試料と
した。DNA量の測定は、Ceriottiの方法
(J.Biol.Chem.,214:39−77,1
955)に従って行なった。試料2.0mlに濃塩酸
1.0ml及び0.04%インドール溶液1.0mlを
加え、試験官にアルミキャップを被せ、沸騰水浴中で1
0分間加熱した後、氷中で急冷することによって反応を
停止させた。クロロホルム4.0mlで3〜4分間の抽
出を数回繰返し、分光光度計(490nm)でDNA量
を測定した。DNA量(mg)は、骨組織湿重量(g)
当りで計算した。Measurement of Deoxyribonucleic Acid (DNA) Content in Bone Tissue The diaphyseal tissue and metaphyseal tissue of the femur were washed with a cold 0.25 M sucrose solution, and after removing water, the wet weight was measured. This was crushed in 4.0 ml of 0.1 N NaOH,
Shake for 4 hours and extract. Thereafter, centrifugation was performed at 3000 rpm for 5 minutes, and the supernatant fraction was used as a sample for DNA measurement. The amount of DNA was measured according to the method of Ceriotti (J. Biol. Chem., 214: 39-77, 1).
955). 1.0 ml of concentrated hydrochloric acid and 1.0 ml of a 0.04% indole solution were added to 2.0 ml of the sample, and the tester was covered with an aluminum cap.
After heating for 0 minutes, the reaction was stopped by quenching in ice. Extraction with 4.0 ml of chloroform for 3 to 4 minutes was repeated several times, and the amount of DNA was measured with a spectrophotometer (490 nm). The amount of DNA (mg) is the bone tissue wet weight (g)
Calculated per hit.
【0013】統計処理法 各々の測定値の有意差検定は、Student’s t
−testを用いて行なった。危険率5%以下のものを
有意差有りとした。Statistical processing method The significance test of each measured value was performed by Student's
Performed using -test. Those with a risk factor of 5% or less were determined to have a significant difference.
【0014】実験結果の説明 納豆製造過程で生成する煮汁乾燥粉末を懸濁した試料液
(100mg煮汁/ml)をラットに体重100g当り
1mlを2週間経口投与したときの大腿骨の骨幹部組織
と骨幹端部組織の骨成分の変動について調べた。結果を
表1に示す。骨幹部組織中のカルシウム量並びにDNA
量は煮汁投与により有意に増加した。また更に、骨幹端
部組織中のカルシウム量、アルカリ性ホスファターゼ活
性及びDNA量は煮汁投与により有意に増大した。この
結果から、サポニン(66μg/ml)、ダイズイン
(77μg/ml)、ダイゼイン(0.6μg/m
l)、ゲニスチン(58μg/ml)及びゲニスティン
(0.6μg/ml)を含有する煮汁組成物が、骨形成
促進による骨成長や老化に伴う骨代謝活性の減弱による
骨増量の減少を防止し得る有効な組成をもつ食品素材で
あることが判明した。なお、煮汁組成物と等濃度のサポ
ニン(66μg/ml)、ダイズイン(77μg/m
l)、ダイゼイン(0.6μg/ml)並びにゲニステ
ィン(0.6μg/ml)をそれぞれ単独に経口投与し
た場合には、上記骨成分の有意な増加は認められなかっ
た。このことから、煮汁経口投与による骨成分の増加効
果は、上記成分の複合的相乗効果に基づくことが判明し
た。これにより、老化性骨粗鬆症の発症を煮汁組成物の
摂取により予防できる可能性を開いたものである。Description of experimental results [0014] The diaphyseal tissue of the femur when the rat was orally administered with a sample solution (100 mg of broth / ml) in which dried broth powder produced in the process of natto production was suspended orally at a dose of 1 ml per 100 g of body weight for 2 weeks. The change of the bone component of the metaphyseal tissue was examined. Table 1 shows the results. Calcium content and DNA in diaphyseal tissue
The amount was significantly increased by the administration of broth. Furthermore, the amount of calcium, alkaline phosphatase activity and the amount of DNA in the metaphyseal tissue were significantly increased by the administration of broth. From the results, saponin (66 μg / ml), soybean (77 μg / ml), daidzein (0.6 μg / m
l), a broth composition containing genistin (58 μg / ml) and genistein (0.6 μg / ml) can prevent bone growth due to promotion of bone formation and decrease in bone mass due to decrease in bone metabolic activity due to aging. It was found that the food material had an effective composition. In addition, saponin (66 μg / ml) and soybean (77 μg / m
l), daidzein (0.6 μg / ml) and genistein (0.6 μg / ml) were orally administered alone, but no significant increase in the bone component was observed. From this, it was found that the effect of increasing the bone component by oral administration of the broth was based on the combined synergistic effect of the above components. This opens up the possibility that the onset of aging osteoporosis can be prevented by ingesting the broth composition.
【0015】[0015]
【表1】ラット大腿骨骨組織中の骨成分の煮汁経口投与
による増量 各値は、6匹のラットの骨組織の平均値±標準誤差を示
す。[Table 1] Bone components in rat femur bone tissue were increased by oral administration of broth Each value represents the mean ± standard error of bone tissue of 6 rats.
【0016】本発明の組成物を含有する食品素材は、副
作用が全くない抗骨粗鬆症効果を有することから、若い
時期から日常的に骨粗鬆症の予防を目的に摂取すること
ができるため、個人の老後の生活の質を守るだけではな
く、高齢化社会の医療費削減への貢献が期待できる。同
時に、本発明により提供できる組成物をもった食品素材
は、栄養成分の強化も行なうことができる。The food material containing the composition of the present invention has an anti-osteoporosis effect without any side effects, and can be taken on a daily basis for the purpose of preventing osteoporosis from a young age. In addition to protecting the quality of life, it can be expected to contribute to reducing medical costs in an aging society. At the same time, food materials with the composition provided by the present invention can also enhance nutritional components.
【0017】安全性試験 実施例で調製した粉末試料液の急性毒性試験を以下の方
法で行なった。 <試験方法>4週齢のウイスター系雄性ラットを1群1
0匹使用した。被検物質の投与が個体体重に対して1g
/100g体重及び10g/100gの2群を編成し、
18時間絶食後、胃ゾンデを用いて強制経口投与した。
ラットは恒温恒湿の条件で飼育し、投与日を0として各
個体の体重を測定しつつ、14日間一般症状及び生死の
状態を観察した。この間、水と餌は自由に与えた。Safety Test The acute toxicity test of the powder sample solution prepared in the examples was performed by the following method. <Test Method> One 4-week-old male Wistar rat was grouped 1
0 animals were used. Administration of test substance is 1 g per individual body weight
/ 100g body weight and 10g / 100g
After an 18-hour fast, gavage administration was performed using a gastric tube.
The rats were bred under constant temperature and humidity conditions, and the body weight of each individual was measured with the administration day being 0, and the general symptoms and the state of life and death were observed for 14 days. During this time, water and food were provided ad libitum.
【0018】<試験結果>粉末試料液の投与は、死亡例
は認められず、体重も順調に増加した。また、外観も通
常のラットと何ら変わりがなかった。したがって、被検
物質ともLD50は10g/100gより大きく、極め
て安全な組成物であることがわかった。また、本試料液
は天然食品成分をもった素材であることから慢性毒性に
関しても極めて安全性の高い素材であると判断される。<Test Results> In the administration of the powder sample solution, no fatal cases were observed, and the body weight increased steadily. The appearance was not different from that of a normal rat. Therefore, the LD50 of each test substance was greater than 10 g / 100 g, indicating that the composition was an extremely safe composition. Further, since this sample liquid is a material having a natural food component, it is determined that the sample liquid is extremely safe with respect to chronic toxicity.
【0019】[0019]
【実施例】 実施例1 粉末素材 大豆煮汁乾燥粉末(サポニン 66mg/100g,ダイジン 77mg/1 00g,ダイゼイン 0.6mg/100g,ゲニスチン 58mg/100g ,ゲニスティン 0.6mg/100g) ・・・・・・700g トウモロコシデンプン ・・・・・・280g 抽出トコフェロール ・・・・・・ 20g 上記原料を高速ミキサーにて混合して均一な粉末が得ら
れた。この粉末は様々な食品に混合可能である。EXAMPLES Example 1 Powder Material Soybean Boiled Dry Powder (Saponin 66mg / 100g, Daizin 77mg / 100g, Daidzein 0.6mg / 100g, Genistin 58mg / 100g, Genistin 0.6mg / 100g) 700 g corn starch 280 g extracted tocopherol 20 g The above raw materials were mixed by a high-speed mixer to obtain a uniform powder. This powder can be mixed with various foods.
【0020】 実施例2 錠剤 大豆煮汁乾燥粉末(実施例1と同様の成分を含む) ・・・・100g トウモロコシデンプン ・・・・125g 結晶セルロース ・・・・ 25g 上記成分を均一に混合して、7.5%ヒドロキシピロピ
ルセルロース水溶液200mlを加え、押出し造粒機に
より、直径0.5mmスクリーンを用いて顆粒とし、直
ちにエルメライザーにより丸めた後、乾燥して顆粒剤と
した。Example 2 Tablets Soybean broth dried powder (containing the same ingredients as in Example 1) 100 g corn starch 125 g crystalline cellulose 25 g The above ingredients were mixed uniformly. 200 ml of a 7.5% aqueous hydroxypropyl cellulose solution was added, granulated by an extrusion granulator using a screen with a diameter of 0.5 mm, immediately rounded by an elmerizer, and dried to obtain granules.
【0021】大豆煮汁及び胚軸の乾燥方法と適用の範囲 大豆食品加工時に発生する胚軸や煮汁は、直ちに乾燥し
て水分を飛ばさないと、腐敗微生物等が増殖し、成分組
成が変化してしまう。乾燥方法としては、通常食品の乾
燥に用いる手法の全てについて適用することができる。Method of drying soybean broth and hypocotyl and range of application Hypocotyl and broth generated during processing of soybean food must be dried immediately to remove water, and spoilage microorganisms and the like will proliferate and the composition of components will change. I will. As a drying method, all the methods usually used for drying foods can be applied.
【0022】[0022]
【発明の効果】大豆食品加工中に生成する胚軸や煮汁
(サポニン、ダイズイン、ダイゼイン、ゲニスチン及び
ゲニスティンを含有)を食品素材とした組成物は、強い
骨成長並びに骨形成促進効果及び骨塩量増加効果を有
し、健康食品として摂取しやすい顆粒剤として服用する
ことができるのみならず、日常的に食する食品として違
和感なく容易に摂取できるので、高齢者の骨粗鬆症の治
療及び予防に特に有用であり、若年層においても、食生
活の偏重により生じる骨成長や骨形成の遅延を予防する
のに高い効果を奏する。更に、骨形成や骨代謝の異常に
よって生じる骨折、骨軟化症、骨粗鬆症、リュウマチ性
骨減少症や腰背痛の予防食品や医薬品として有用であ
る。EFFECTS OF THE INVENTION A composition using a hypocotyl or broth (containing saponin, soybean, daidzein, genistin and genistein) produced during the processing of soybean food as a food material has a strong bone growth and bone formation promoting effect and bone mineral content. Especially useful for the treatment and prevention of osteoporosis in the elderly, as it has an increasing effect and can be taken not only as granules that are easy to be taken as health foods, but also as a food to eat on a daily basis without discomfort Therefore, even for young people, it is highly effective in preventing a delay in bone growth and bone formation caused by an overweight diet. Further, it is useful as a preventive food or pharmaceutical for fractures, osteomalacia, osteoporosis, rheumatic osteopenia and low back pain caused by abnormal bone formation and bone metabolism.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 35/78 A61K 35/78 J 4C088 // A23L 1/20 A23L 1/20 A 1/30 1/30 B C07D 311/36 C07D 311/36 C07H 15/256 C07H 15/256 Z 17/07 17/07 Fターム(参考) 4B018 LE01 LE03 MD58 ME05 MF04 MF06 MF08 4B020 LB24 LB30 LC05 LC08 LG01 LK05 LP04 LP20 4C057 BB02 JJ52 KK08 4C062 EE43 4C086 AA01 AA02 BA08 EA11 MA01 ZA96 ZA97 4C088 AB61 AC04 CA05 NA06 NA07 ZA96 ZA97 ──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 35/78 A61K 35/78 J4C088 // A23L 1/20 A23L 1/20 A 1/30 1/30 B C07D 311/36 C07D 311/36 C07H 15/256 C07H 15/256 Z 17/07 17/07 F term (reference) 4B018 LE01 LE03 MD58 ME05 MF04 MF06 MF08 4B020 LB24 LB30 LC05 LC08 LG01 LK05 LP04 LP20 4C057 BB02 JJ52 4C062 EE43 4C086 AA01 AA02 BA08 EA11 MA01 ZA96 ZA97 4C088 AB61 AC04 CA05 NA06 NA07 ZA96 ZA97
Claims (3)
スチン及びゲニスティンを主たる有効成分とすることを
特徴とする骨形成促進及び抗骨粗鬆症組成物。1. An osteogenesis-promoting and anti-osteoporosis composition comprising saponin, daidzin, daidzein, genistin and genistein as main active ingredients.
スチン及びゲニスティンが大豆煮汁あるいは大豆や大豆
胚軸由来である請求項1記載の組成物。2. The composition according to claim 1, wherein the saponin, daidzin, daidzein, genistin and genistin are derived from soybean broth or soybean or soybean hypocotyl.
上,ダイジン50mg以上,ダイゼイン0.4mg以
上,ゲニスチン40mg以上及びゲニスティン0.4m
g以上である請求項1〜3のいずれか1項に記載の組成
物。3. Saponin 50 mg or more, daidzin 50 mg or more, daidzein 0.4 mg or more, genistin 40 mg or more, and genistein 0.4 m in 100 g of solid matter
The composition according to any one of claims 1 to 3, which is not less than g.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10370606A JP2000191526A (en) | 1998-12-25 | 1998-12-25 | Composition for stimulating formation of bone and preventing and treating bone osteoporosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10370606A JP2000191526A (en) | 1998-12-25 | 1998-12-25 | Composition for stimulating formation of bone and preventing and treating bone osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000191526A true JP2000191526A (en) | 2000-07-11 |
Family
ID=18497297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10370606A Pending JP2000191526A (en) | 1998-12-25 | 1998-12-25 | Composition for stimulating formation of bone and preventing and treating bone osteoporosis |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2000191526A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074308A1 (en) * | 2001-03-15 | 2002-09-26 | Roche Vitamins Ag | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
WO2003068218A1 (en) * | 2002-02-15 | 2003-08-21 | N.V. Nutricia | Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k |
WO2004037236A1 (en) * | 2002-10-25 | 2004-05-06 | KEMIN FOODS, L. C. d/b/a KEMIN HEALTH, L. C. | OSTEOGENESIS PROMOTER CONTAINING β-CRYPTOXANTHIN AS THE ACTIVE INGREDIENT |
JP2010088442A (en) * | 2001-12-11 | 2010-04-22 | Soc Des Produits Nestle Sa | Composition for promotion of bone growth and maintenance of bone health |
CN104324220A (en) * | 2014-11-24 | 2015-02-04 | 吴玲 | Traditional Chinese medicine for treating hyperostosis |
CN105396091A (en) * | 2015-11-25 | 2016-03-16 | 王雅芳 | Traditional Chinese medicine formula composition for treating scapulohumeral periarthritis |
CN105395773A (en) * | 2015-11-25 | 2016-03-16 | 王雅芳 | Method for preparing scapulohumeral periarthritis recipe |
-
1998
- 1998-12-25 JP JP10370606A patent/JP2000191526A/en active Pending
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074308A1 (en) * | 2001-03-15 | 2002-09-26 | Roche Vitamins Ag | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
JP2004532829A (en) * | 2001-03-15 | 2004-10-28 | ディーエスエム アイピー アセッツ ビー.ブイ. | A composition for preventing osteoporosis, comprising a combination of isoflavones and polyunsaturated fatty acids |
EP1852115A1 (en) * | 2001-03-15 | 2007-11-07 | DSM IP Assets B.V. | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
EP1854462A1 (en) * | 2001-03-15 | 2007-11-14 | DSMIP Assets B.V. | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
CN100389765C (en) * | 2001-03-15 | 2008-05-28 | Dsmip资产有限公司 | Composition for preventing osteoporosis containing combination of isoflavones and polyunsaturated fatty acids |
JP2010088442A (en) * | 2001-12-11 | 2010-04-22 | Soc Des Produits Nestle Sa | Composition for promotion of bone growth and maintenance of bone health |
WO2003068218A1 (en) * | 2002-02-15 | 2003-08-21 | N.V. Nutricia | Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k |
WO2004037236A1 (en) * | 2002-10-25 | 2004-05-06 | KEMIN FOODS, L. C. d/b/a KEMIN HEALTH, L. C. | OSTEOGENESIS PROMOTER CONTAINING β-CRYPTOXANTHIN AS THE ACTIVE INGREDIENT |
US8148431B2 (en) | 2002-10-25 | 2012-04-03 | Kemin Health, L.C. | Osteogenesis promoter containing β-cryptoxanthin as the active ingredient |
CN104324220A (en) * | 2014-11-24 | 2015-02-04 | 吴玲 | Traditional Chinese medicine for treating hyperostosis |
CN105396091A (en) * | 2015-11-25 | 2016-03-16 | 王雅芳 | Traditional Chinese medicine formula composition for treating scapulohumeral periarthritis |
CN105395773A (en) * | 2015-11-25 | 2016-03-16 | 王雅芳 | Method for preparing scapulohumeral periarthritis recipe |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002358530B2 (en) | Food or pet food composition containing plant extract for bone health | |
JP2016517438A (en) | How to maintain and improve muscle function | |
JP2016520050A (en) | How to enhance aging muscle regeneration | |
US6753312B2 (en) | Food products and dietary supplements containing phenolated proteins and process for preparing the same | |
JP4637052B2 (en) | Bone mass enhancing composition containing pollen cargo as an active ingredient | |
US20090069217A1 (en) | Nutrient composition | |
CN1678327B (en) | Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation | |
TW200406159A (en) | Calcium absorption enhancer | |
JP4390428B2 (en) | Calcium-containing tissue strengthening agent | |
JP2000191526A (en) | Composition for stimulating formation of bone and preventing and treating bone osteoporosis | |
JP3749978B2 (en) | Bone formation enhancing composition exhibiting anti-osteoporosis effect | |
JP2002234844A (en) | Bone density improver and utilization thereof | |
JP3459932B2 (en) | Anti-osteoporosis composition | |
JP5281895B2 (en) | Calcium absorption promoter | |
JP2001302539A (en) | Bone strengthening agent, bone strengthening food and feed composition | |
JP4808218B2 (en) | Protein hydrolyzate with anti-diabetic activity | |
JP3250071B2 (en) | Anti-osteoporosis composition | |
EP1170013A1 (en) | Drugs, foods, drinks and feeds containing cocoa component | |
JP2000139411A (en) | Food and drink including isoflavone together with peptide | |
AU2006347124B2 (en) | Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus Acacia | |
AU2006347121B2 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia | |
KR20110062429A (en) | Bone Growth Promoting Composition Containing Gelatin Derivative Enzyme | |
JP3923052B2 (en) | Soy food for promoting bone formation and preventing bone mineral loss | |
JP3749647B2 (en) | Blood ammonia reducing agent | |
US20080161385A1 (en) | Composition Inhibiting Sex Hormone-Binding Globulin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041119 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050520 |